Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Could blood sugar drugs slow Alzheimer's? The science looked promising, but the biggest test yet — Novo Nordisk's phase 3 EVOKE trials of oral semaglutide in nearly 3,800 patients — showed no meaningful slowing of cognitive decline. Researchers are now shifting focus toward earlier intervention and prevention-based strategies, including the new $100M PROTECT-Cog global trial.
The idea of repurposing diabetes drugs for Alzheimer's disease (AD) was built on compelling shared biology. GLP-1 receptor agonists (GLP-1RAs) like liraglutide and semaglutide showed real promise in animal models — reducing amyloid and tau buildup, curbing neuroinflammation, and protecting synapses. Real-world data added fuel: a 2022 pooled analysis of cardiovascular outcome trials found GLP-1RAs were associated with a 53% lower dementia rate compared to placebo in type 2 diabetes patients.
But randomized trials have told a more sobering story. The phase 2b ELAD trial of liraglutide (n=204) missed its primary endpoint of improving brain glucose metabolism, and the much larger phase 3 EVOKE/EVOKE+ trials of oral semaglutide (n=3,808) showed no separation in cognitive decline over two years. Some CSF biomarkers did improve modestly, hinting at biological activity — but not enough to move the clinical needle. Researchers point to limited drug penetration into the brain, a study population with few diabetes patients, and late-stage disease timing as possible explanations.
Key Takeaways:
Why it matters: After years of hope, the failure of semaglutide in established AD is a significant reality check — but it's redirecting the field toward earlier, potentially more impactful intervention windows. If prevention trials succeed, the implications for the millions at risk of Alzheimer's could be enormous.
